Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Early pseudoprogression following chemoradiotherapy in glioblastoma patients: The value of RANO evaluation
Publication

Publications

Early pseudoprogression following chemoradiotherapy in glioblastoma patients: The value of RANO evaluation

Title
Early pseudoprogression following chemoradiotherapy in glioblastoma patients: The value of RANO evaluation
Type
Article in International Scientific Journal
Year
2013
Authors
Linhares, P
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Carvalho, B
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Figueiredo, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Reis, RM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Vaz, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Title: Journal of OncologyImported from Authenticus Search for Journal Publications
Vol. 2013
Pages: 1-9
ISSN: 1687-8450
Publisher: Hindawi
Indexing
Other information
Authenticus ID: P-008-E4Q
Abstract (EN): Introduction. The aim of this study was to determine the frequency of pseudoprogression in a cohort of glioblastoma (GBM) patients following radiotherapy/temozolomide (RT/TMZ) by comparing Macdonald criterial to Response Assessment in Neuro-Oncology (RANO) criteria. The impact on prognosis and survival analysis was also studied. Materials and Methods. All patients receiving RT/TMZ for newly diagnosed GBM from January 2005 to December 2009 were retrospectively evaluated, and demographic, clinical, radiographic, treatment, and survival data were reviewed. Updated RANO criteria were used for the evaluation of the pre-RT and post-RT MRI and compared to classic Macdonald criteria. Survival data was evaluated using the Kaplan-Meier and log-rank analysis. Results and Discussion. 70 patients were available for full radiological response assessment. Early progression was confirmed in 42 patients (60%) according to Macdonald criteria and 15 patients (21%) according to RANO criteria. Pseudoprogression was identified in 10 (23.8%) or 2 (13.3%) patients in Macdonald and RANO groups, respectively. Cumulative survival of pseudoprogression group was higher than that of true progression group and not statistically different from the non-progressive disease group. Conclusion. In this cohort, the frequency of pseudoprogression varied between 13% and 24%, being overdiagnosed by older Macdonald criteria, which emphasizes the importance of RANO criteria and new radiological biomarkers for correct response evaluation. © 2013 Paulo Linhares et al.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Angiogenesis and breast cancer (2010)
Another Publication in an International Scientific Journal
Fernando Schmitt; Longatto Filho, A; Lopes, JM
Oncogenic HPV types infection in adolescents and university women from North Portugal: From self-sampling to cancer prevention (2011)
Article in International Scientific Journal
Silva, J; Ribeiro, J; Sousa, H; Cerqueira, F; Teixeira, AL; Baldaque, I; Osorio, T; Medeiros, R
Angiogenesis and breast cancer. (2010)
Article in International Scientific Journal
Fernando Schmitt
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-28 at 16:32:38 | Privacy Policy | Personal Data Protection Policy | Whistleblowing